Neuroscience

Dementia
#Alzheimer's #Dementia #FDA #Lundbeck #Otsuka #Phase III trial

FDA approves first drug for agitation due Alzheimer’s dementia

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a common neuropsychiatric symptom in Alzheimer’s dementia… Read More

#News #Regulatory

Laboratory equipment
#Expansion #Gate Neurosciences #Lab space #Major depressive disorder #Neuroscience

Gate Neurosciences expands research operations

Gate Neurosciences has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois. The company hopes to further build the translational biomarker data package supporting its NMDA receptor modulator portfolio and advance foundational mechanism insights behind its synaptic function-enhancing molecules. Read More

#News

Amygdala
#Anxiety disorder #Drug discovery #Neuroscience #Preclinical investigations #University of Bristol #University of Exeter

Discovery represents the ‘first step’ to better anti-anxiety drugs

A team of scientists have discovered that modification of a gene in the brain can reduce anxiety levels, offering an exciting novel drug target for anxiety disorders. The discovery, led by researchers at the Universities of Bristol and Exeter in the UK, is published in Nature… Read More

#News

#Alzheimer's #Biomarkers #Digital biomarkers #Neurodegenerative disorders #Neuroscience

Why digital biomarkers will power tomorrow’s Alzheimer’s therapies

Listen to this article on the DDW Podcast: Rivka Kreitman, CIO of NeuraLight explores the landscape of therapies for Alzheimer’s and explains why digital biomarkers are key to combatting the disease. Neurodegenerative diseases – the collection of progressive conditions characterised by neuron cell damage and death and subsequent loss of motor… Read More

#Exclusive Content

#Agilent #Mitochondria #Neurodegenerative disorders #Neurology #Rare disease #Webinar

Watch now: Neuronal metabolism and early drug discovery

A new webinar is now available to watch anytime. CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the… Read More

Webinar date:
Brought to you by Agilent
#News

Hormones in the brain concept
#Antidepressants #Depression #Evecxia Therapeutics #Major depressive disorder #Phase I trial #Psychiatry

New adjunctive antidepressant elevates serotonin in Phase I trial

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. The company is also planning a Phase II adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a… Read More

#News

Covid/neuroscience concept
#AI / data analytics / healthtech / informatics #Drug discovery #Neuroscience

DDW Spring issue out now

The Spring 2023 issue of Drug Discovery World Magazine is out now. Featuring a Therapeutic Spotlight on Neuroscience, the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Key features of the… Read More

#Editor's Choice #News

World Parkinson's Day
#Drug development #Drug discovery #Neurodegenerative disorders #Parkinson's

World Parkinson’s Day: New drug research

It is World Parkinson’s Day (11 April), raising awareness of the fastest growing neurological condition in the world. There is currently no cure, and although there are therapeutics to manage the symptoms, these usually bring side-effects, and so there is still need for new therapeutic options. Here, we take a… Read More

#Exclusive Content #Trending News

Vascular endothelial growth factor A
#Drug targets #Gilead Sciences #GlobalData #Krystal Biotech #Neurodegenerative disorders #Regenerative Medicine

Regenerative medicine switches to VEGF as top drug target

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. According to analysts GlobalData, early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development. Surprisingly, the majority of the targets… Read More

#News #Trends & Analysis

Female medical researcher
#Genetics #Genetics / genomics #Icahn School of Medicine #Neuroscience #Psychiatry #Schizophrenia

Researchers identify genes that may increase schizophrenia risk

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-centre study further demonstrated that the schizophrenia risk conferred by these… Read More

#News

#Biotechnology #Drug development #Neurodegenerative disorders #Neuroscience #Seed funding

€28M for neurodegenerative disease treatments

Teitur Trophics, a biotech company developing new treatments for patients suffering from neurodegenerative diseases, has complete a €28M Series A financing.   The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable… Read More

#Business & Investment #News

Brain Awareness Week
#Brain #Brain Awareness Week #Brain disease #Dementia #Drug discovery #Parkinson's #Stroke

Brain Awareness Week: the wonders of brain science

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. Brain Awareness Week is an annual global campaign that takes place from March 13-19, aimed at raising awareness and support for brain science and issues related to the brain and… Read More

#Exclusive Content

#Autoimmune disease #Biopharmaceuticals #Covid-19 #Long Covid #Multiple sclerosis #Neurodegenerative disorders

€25 million to support clinical developments against long Covid

GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of Covid-19, (PASC, post-Covid or long Covid), has entered into a credit agreement for a total amount of up to €25 million with the… Read More

#News

#Anxiety disorder #Biotherapeutics #Neuroscience #Postpartum depression

Potential treatment for anxiety and postpartum depression 

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the… Read More

#News

Neurons in Parkinson's disease
#Genetics / genomics #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's #University of Queensland

Focus on autophagy could lead to more effective Parkinson’s drugs

Researchers have identified that a gene associated with an increased risk of Parkinson’s Disease also contributes to a build-up of cell debris in the brain. Dr Adekunle Bademosi from The Queensland Brain Institute said the discovery could change the focus of Parkinson’s Disease treatment. Without the… Read More

#News